BRIEF — Solvonis Therapeutics Signs MoU With Portugal's National Addiction Institute
Oct 13 (Reuters) — Solvonis Therapeutics PLC: Solvonis Therapeutics - Signs Mou With Portugal's National Addiction Institute For Svn-001 Phase 3 Trial Expansion Source text:... Further company coverage: SVNS.L (Reuters.Briefs@thomsonreuters.com)